Group items tagged

The Department of Defense (DoD) announces the Fiscal Year 2015 Defense University Research Instrumentation Program (DURIP), a part of the University Research Initiative (URI). DURIP is designed to improve the capabilities of U.S. institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment.

The following programs have due dates that fall between October 1 - 25, 2013, and these dates are being revised due to the Federal  government shutdown. These revised dates apply whether the proposal is being submitted via the NSF FastLane System or  Grants.gov. Due to compressed proposal deadlines resulting from the shutdown, proposers are advised that they may experience a  delay when contacting IT Help Central with technical support questions. Frequently asked questions regarding these date changes  are available on the Resumption of Operations page on the NSF website at: http://www.nsf.gov/bfa/dias/policy/postshutdown.jsp. 

The Defense Sciences Office (DSO) at the Defense Advanced Research Projects Agency (DARPA) is soliciting innovative research proposals in the areas of: automated and sensor fused data analytics, network infrastructure and system integration, and interfaces and interoperability to support a networked system for the detection, interdiction, and deterrence of clandestine weapons of mass destruction (WMD) activities. Proposed research should investigate innovative approaches that enable revolutionary advances in science, devices, and systems. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

The purpose of this FOA is to promote the development of in vitro microphysiological systems in modeling human diseases and conditions that mimic the pathology in major organs and tissues in the human body, when exposed to the extreme environments of space, and the use of these models at the International Space Station-U.S. National Laboratory (ISS-NL) to facilitate the assessment of biomarkers, bioavailability, efficacy, and toxicity of therapeutic agents prior to entry into clinical trials. Funds from the NIH will be made available through the UG3/UH3 cooperative agreement mechanism. During the initial two-year UG3 phase, support will be provided to develop robust models that recapitulate the progression and pathology of human diseases and conditions exposed to prolonged microgravity environment. Following administrative review, the two-year UH3 phase will build upon successful UG3 models to demonstrate the functional utility of the models for more defined experiments at the ISS-NL. It is anticipated that these studies will lead to identification of novel treatment mechanisms through better understanding of disease biology, drug screening, assessment of candidate therapies for efficacy and safety assessments, and establishing the pre-clinical foundation that will inform clinical trial design on Earth.